46 studies found for:    Open Studies | "hospital of central connecticut"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "hospital of central connecticut"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Cardiovascular Inflammation Reduction Trial
Condition: Cardiovascular Disease
Interventions: Drug: Methotrexate;   Drug: Placebo
2 Recruiting Connect® MM- The Multiple Myeloma Disease Registry
Condition: Multiple Myeloma
Intervention:
3 Recruiting MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ
Condition: Ductal Breast Carcinoma In Situ
Interventions: Procedure: Magnetic Resonance Imaging;   Procedure: Therapeutic Conventional Surgery;   Procedure: Therapeutic Surgical Procedure;   Radiation: Radiation Therapy;   Drug: Endocrine Therapy;   Other: Quality-of-Life Assessment;   Other: Laboratory Biomarker Analysis;   Other: Cytology Specimen Collection Procedure
4 Recruiting Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Conditions: Stage IB Non-Small Cell Lung Carcinoma;   Stage IIA Non-Small Cell Lung Carcinoma;   Stage IIB Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer
Interventions: Drug: Crizotinib;   Other: Laboratory Biomarker Analysis;   Other: Placebo
5 Recruiting Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Conditions: Large Cell Lung Carcinoma;   Lung Adenocarcinoma;   Stage IB Non-Small Cell Lung Carcinoma;   Stage IB Squamous Cell Lung Carcinoma;   Stage IIA Non-Small Cell Lung Carcinoma;   Stage IIA Squamous Cell Lung Carcinoma;   Stage IIB Non-Small Cell Lung Carcinoma;   Stage IIB Squamous Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIA Squamous Cell Lung Carcinoma
Interventions: Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis
6 Recruiting Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
Conditions: Stage IB Non-Small Cell Lung Carcinoma;   Stage IIA Non-Small Cell Lung Carcinoma;   Stage IIB Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer
Interventions: Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Placebo
7 Recruiting Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer
Conditions: Recurrent Squamous Cell Lung Carcinoma;   Stage IV Squamous Cell Lung Carcinoma
Interventions: Drug: Docetaxel;   Biological: Durvalumab;   Drug: Erlotinib Hydrochloride;   Drug: FGFR Inhibitor AZD4547;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Drug: Palbociclib;   Biological: Rilotumumab;   Drug: Taselisib
8 Recruiting Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
Conditions: Estrogen Receptor Positive;   HER2/Neu Negative;   Male Breast Carcinoma;   Progesterone Receptor Positive;   Recurrent Breast Carcinoma;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: Entinostat;   Drug: Exemestane;   Drug: Goserelin Acetate;   Other: Laboratory Biomarker Analysis;   Other: Placebo;   Other: Quality-of-Life Assessment
9 Recruiting Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: clofarabine;   Drug: daunorubicin hydrochloride;   Other: clinical observation;   Drug: cytarabine;   Drug: decitabine;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment;   Other: questionnaire administration
10 Recruiting Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer
Conditions: Endometrial Clear Cell Adenocarcinoma;   Estrogen Receptor Negative;   Ovarian Clear Cell Cystadenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Recurrent Uterine Corpus Carcinoma
Interventions: Drug: Dasatinib;   Other: Laboratory Biomarker Analysis
11 Recruiting Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery
Conditions: Stage IB Breast Cancer;   Stage II Breast Cancer
Interventions: Radiation: regional nodal XRT;   Radiation: chestwall XRT;   Radiation: WBI
12 Recruiting Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma
Conditions: Stage II Diffuse Large B-Cell Lymphoma;   Stage III Diffuse Large B-Cell Lymphoma;   Stage IV Diffuse Large B-Cell Lymphoma
Interventions: Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Drug: Prednisone;   Biological: Rituximab;   Drug: Vincristine Sulfate
13 Recruiting Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
Conditions: Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Non-Small Cell Lung Cancer
Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Crizotinib;   Drug: Erlotinib Hydrochloride;   Drug: Etoposide;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
14 Recruiting Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission
Condition: Leukemia, Myeloid, Acute
Interventions: Drug: 300 mg Oral Azacitidine;   Drug: Placebo
15 Recruiting Chemoradiation Therapy and Ipilimumab in Treating Patients With Locally Advanced Cervical Cancer
Conditions: Cervical Adenocarcinoma;   Cervical Adenosquamous Carcinoma;   Cervical Squamous Cell Carcinoma;   Stage IB Cervical Cancer;   Stage IIA Cervical Cancer;   Stage IIB Cervical Cancer;   Stage IIIB Cervical Cancer;   Stage IVA Cervical Cancer
Interventions: Drug: Cisplatin;   Other: Cytology Specimen Collection Procedure;   Radiation: External Beam Radiation Therapy;   Radiation: Internal Radiation Therapy;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis
16 Recruiting Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma
Conditions: DS Stage I Plasma Cell Myeloma;   DS Stage II Plasma Cell Myeloma;   DS Stage III Plasma Cell Myeloma
Interventions: Drug: Bortezomib;   Drug: Dexamethasone;   Biological: Elotuzumab;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide
17 Recruiting Whole-Brain Radiation Therapy With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer
Conditions: HER2/Neu Positive;   Male Breast Carcinoma;   Metastatic Malignant Neoplasm in the Brain;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Lapatinib Ditosylate;   Radiation: Whole-Brain Radiotherapy
18 Recruiting Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia
Conditions: Choriocarcinoma;   FIGO Stage I Gestational Trophoblastic Tumor;   FIGO Stage II Gestational Trophoblastic Tumor;   FIGO Stage III Gestational Trophoblastic Tumor;   Hydatidiform Mole
Interventions: Biological: Dactinomycin;   Drug: Leucovorin Calcium;   Drug: Methotrexate;   Other: Quality-of-Life Assessment
19 Recruiting Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery
Conditions: Stage I Uterine Sarcoma;   Uterine Corpus Leiomyosarcoma
Interventions: Other: Clinical Observation;   Drug: Docetaxel;   Drug: Doxorubicin Hydrochloride;   Biological: Filgrastim;   Drug: Gemcitabine Hydrochloride;   Biological: Pegfilgrastim
20 Recruiting PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery
Condition: Colorectal Cancer
Interventions: Drug: FOLFOX (chemotherapy);   Other: 5 FUCMT (chemoradiation);   Procedure: surgery;   Procedure: magnetic resonance imaging or endorectal ultrasound

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years